China has granted emergency use approval to a fifth Covid-19 vaccine which uses similar technology to vaccines against hepatitis B, whooping cough and flu. Photo: Handout
China’s production bottleneck ‘could be eased with latest Covid-19 vaccine’
- Emergency use approval paves way for large-scale manufacture of cheap, easy-to-produce vaccines but three doses required
- Non-peer reviewed clinical trial data suggests vaccine is well tolerated and produces immune response against the virus
China has granted emergency use approval to a fifth Covid-19 vaccine which uses similar technology to vaccines against hepatitis B, whooping cough and flu. Photo: Handout
